Country: Canada
Language: English
Source: Health Canada
CALCITONIN (SALMON SYNTHETIC)
SANDOZ CANADA INCORPORATED
H05BA01
CALCITONIN (SALMON SYNTHETIC)
200UNIT
LIQUID
CALCITONIN (SALMON SYNTHETIC) 200UNIT
NASAL
200 U.I / SPRAY BOTTLE
Prescription
PARATHYROID AND ANTIPARATHYROID AGENTS
Active ingredient group (AIG) number: 0111011001; AHFS:
CANCELLED POST MARKET
2013-10-01
Sandoz Calcitonin NS Page 1 of 35 PRODUCT MONOGRAPH PR SANDOZ CALCITONIN NS Synthetic Calcitonin (Salmon) Nasal Spray 200 IU/actuation Bone Metabolism Regulator Sandoz Canada Inc. Date of Revision: 145 Jules-Léger October 12, 2010 Boucherville, Quebec J4B-7K8 Control number : 140901 Sandoz Calcitonin NS Page 2 of 35 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION..................................................3 SUMMARY PRODUCT INFORMATION.............................................................................3 INDICATIONS AND CLINICAL USE...................................................................................3 CONTRAINDICATIONS........................................................................................................4 WARNINGS AND PRECAUTIONS......................................................................................4 ADVERSE REACTIONS........................................................................................................5 DRUG INTERACTIONS........................................................................................................10 DOSAGE AND ADMINISTRATION....................................................................................11 OVERDOSAGE ……………………………………………………………………….........12 ACTION AND CLINICAL PHARMACOLOGY..................................................................12 STORAGE AND STABILITY...............................................................................................15 SPECIAL HANDLING INSTRUCTIONS............................................................................15 DOSAGE FORMS, COMPOSITION AND PACKAGING..................................................15 PART II: SCIENTIFIC INFORMATION..........................................................................16 PHARMACEUTICAL INFORMATION...............................................................................16 CLINICAL TRIALS.................................................... Read the complete document